Pershing Square Sohn Cancer Research Alliance Prize For Young Investigators

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Pershing Square Sohn Cancer Research Alliance is taking applications for its Prize for Young Investigators in Cancer Research.

The prize of $200,000 per year for up to three years is awarded annually to at least five New York City-based scientists, enabling them to continue to pursue research at a stage when traditional funding is lacking. Each prize winner is also given a mentor in the pharmaceutical industry and the opportunity to present his or her work to scientific and business audiences.

In May 2015, PSSCRA awarded the prize to six winners: Timothy Chan, of Memorial Sloan Kettering Cancer Center; Arvin Dar, of the Icahn School of Medicine at Mount Sinai; Evripidis Gavathiotis, of Albert Einstein College of Medicine; Moritz Kircher, of MSKCC; Christine Mayr, of MSKCC; and Sohail Tavazoie, of The Rockefeller University.

In order to apply, applicants must have between two and eight years of experience running their own laboratories and must have a Ph.D., M.D., or M.D.-Ph.D. or equivalent. The deadline to submit a letter of intent is Nov. 9.

More details on the application process, including full eligibility criteria, are available on their website.

YOU MAY BE INTERESTED IN

Cell and gene therapies have made incredible strides over the past decade. The 2024 FDA approvals of the first T-cell receptor therapy for the treatment of metastatic synovial sarcoma and the first tumor-infiltrating lymphocyte therapy for the treatment of unresectable or metastatic melanoma mark a significant turning point for solid tumor treatment.xxx:more
The intersection of diabetes, obesity and cancer represents an important and underappreciated challenge in medicine. Apart from smoking, overweight is now the leading modifiable risk factor for cancer. With the global epidemic of overweight and diabetes driving cancer incidence across multiple organ sites, understanding the metabolic underpinnings of this relationship has never been more critical.
The Pazdurs in their garden with their dog, Cleo. The dog’s full name is Cleopatra, Queen of Denial.In 1999, Rick Pazdur went in for a “perfunctory” final interview at FDA. Thinking it would only take a few minutes, his wife, Mary, decided to wait and have a quick cup of coffee at a nearby restaurant—Hooters.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login